Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Deloitte
Moodys
Accenture
Merck
Federal Trade Commission
Boehringer Ingelheim
Mallinckrodt
Medtronic
Harvard Business School

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203255

« Back to Dashboard

NDA 203255 describes SIGNIFOR LAR, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the SIGNIFOR LAR profile page.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this compound. Additional details are available on the pasireotide pamoate profile page.

Summary for 203255

Tradename:1
Applicant:1
Ingredient:1
Patents:4

Suppliers and Packaging for NDA: 203255

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255 NDA Novartis Pharmaceuticals Corporation 0078-0641 0078-0641-81 1 VIAL, SINGLE-USE in 1 KIT (0078-0641-81) > 1 KIT in 1 VIAL, SINGLE-USE (0078-0641-61) * 6 mL in 1 VIAL, SINGLE-USE * 2 mL in 1 SYRINGE
SIGNIFOR LAR pasireotide pamoate POWDER;INTRAMUSCULAR 203255 NDA Novartis Pharmaceuticals Corporation 0078-0642 0078-0642-81 1 VIAL, SINGLE-USE in 1 KIT (0078-0642-81) > 1 KIT in 1 VIAL, SINGLE-USE (0078-0642-61) * 6 mL in 1 VIAL, SINGLE-USE * 2 mL in 1 SYRINGE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAMUSCULARStrengthEQ 20MG BASE/VIAL
Approval Date:Dec 15, 2014TE:RLD:Yes
Regulatory Exclusivity Expiration:Dec 14, 2017
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Dec 15, 2017
Regulatory Exclusivity Use:NEW PRODUCT
Regulatory Exclusivity Expiration:Dec 15, 2021
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY

Expired Orange Book Patents for NDA: 203255

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-003Dec 15, 2014► Subscribe► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-001Dec 15, 2014► Subscribe► Subscribe
Novartis Pharms CorpSIGNIFOR LARpasireotide pamoatePOWDER;INTRAMUSCULAR203255-002Dec 15, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Daiichi Sankyo
Cipla
Mallinckrodt
Novartis
Baxter
Farmers Insurance
McKinsey
Covington
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot